Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 targeted T cells
- Development stage
- Phase 2
- Lead developer
- The Christie
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NY-ESO-1 targeted T cells refer to an autologous adoptive T-cell therapy designed to treat cancers expressing the New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) antigen. This specific program, investigated by The Christie NHS Foundation Trust, involves the isolation of a patient's own T cells, which are then engineered or selected to recognize the NY-ESO-1 cancer-testis antigen in the context of HLA-A2. NY-ESO-1 is a highly immunogenic protein with expression typically restricted to germ cells but frequently overexpressed in various malignancies, including oesophagogastric cancer. The therapy was evaluated in a Phase II clinical trial (ATTACK-OG; NCT01795976) for patients with advanced gastroesophageal cancer, but the study was terminated in 2017 due to a withdrawal of funding.
- Other names
- NY-ESO-1 Targeted T CellsNY-ESO1 Targeted T CellsNY-ESO 1 Targeted T Cellsautologous NY-ESO-1–targeted T cells
02
Targets
LAGE-1A/HLA-A*02:01 (L Antigen Family Member 1A (LAGE-1A) peptide presented by Human Leukocyte Antigen A*02:01 (HLA-A*02:01))CD3 (T-cell surface glycoprotein CD3)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on NY-ESO-1 targeted T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 targeted T cells.